Neoplasms, Plasma Cell
Showing 1 - 25 of >10,000
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial in Wuhan (CAR-T (CAR-GPRC5D))
Recruiting
- Relapsed/Refractory Multiple Myeloma
- Plasma Cell Leukemia
- CAR-T (CAR-GPRC5D)
-
Wuhan, Hu Bei, ChinaTongji Hospital, Tongji Medical College, Huazhong University of
May 17, 2022
Multiple Myeloma, Plasma Cell Tumor, Malignant Plasma Cell Tumor Trial in Houston (Radiation Therapy)
Recruiting
- Multiple Myeloma
- +2 more
- Radiation Therapy
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Plasma Cell Tumor Trial in Atlanta (Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine)
Active, not recruiting
- Plasma Cell Neoplasm
- Pneumococcal 13-valent Conjugate Vaccine
- Trivalent Influenza Vaccine
-
Atlanta, Georgia
- +1 more
Jan 24, 2022
Multiple Myeloma Trial in Wuhan (Plasma-free procedure)
Completed
- Multiple Myeloma
- Plasma-free procedure
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Feb 10, 2022
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Recruiting
- Multiple Myeloma
- +11 more
- No intervention
-
Beijing, ChinaPeking University First Hospital
Apr 21, 2022
Multiple Myeloma, Amyloidosis, Cryoglobulinemia Trial in Chapel Hill
Recruiting
- Multiple Myeloma
- +8 more
-
Chapel Hill, North CarolinaNorth Carolina Cancer Hospital
Nov 30, 2021
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Capivasertib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Immunophenotyping of Plasma Cells and Immune Effector Cells in
Not yet recruiting
- Multiple Myeloma
- Biological sampling
- (no location specified)
Jun 17, 2022
Lymphoma, Leukemia, Plasma Cell Dyscrasia Trial in San Francisco (Web Application)
Not yet recruiting
- Lymphoma
- +2 more
- Web Application
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 9, 2022
Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor Trial in Miami (T-cell Receptor a/ß Depleted Donor Lymphocyte
Recruiting
- Lymphoid Leukemia, Acute
- +2 more
- T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
-
Miami, FloridaMiami Cancer Institute at Baptist Health, Inc
May 24, 2022
Based on Maintenance Therapy Post Autologous Stem Cell
Recruiting
- Multiple Myeloma
- Autologous Stem Cell Transplant
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Jul 27, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Trametinib
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Trametinib Dimethyl Sulfoxide
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Aug 13, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Defactinib
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Defactinib Hydrochloride
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Tumor, Plasma Cell, Lymphoma Trial in Toulouse (Comprehensive Geriatric Assessment)
Not yet recruiting
- Neoplasm, Plasma Cell
- Lymphoma
- Comprehensive Geriatric Assessment
-
Toulouse, FranceUniversity Hospital Toulouse
May 17, 2022
ctDNA Methylation Sequencing for Myeloma
Recruiting
- Multiple Myeloma
- plasma circulation DNA methylation sequencing
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
Oct 11, 2022
Multiple Myeloma Trial in Saint Petersburg (Melphalan, Nivolumab, Autologous Stem Cell Transplantation)
Recruiting
- Multiple Myeloma
- Melphalan
- +2 more
-
Saint Petersburg, Russian FederationBoris V Afanasyev, MD, Prof.
Apr 4, 2022
Multiple Myeloma, Tumors, Tumors, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide)
Not yet recruiting
- Multiple Myeloma
- +7 more
- Belantamab Mafodotin-Blmf
- +3 more
- (no location specified)
Mar 4, 2022
Myeloma Multiple Trial (Traditional Control, Oral Nutritional Supplement)
Not yet recruiting
- Myeloma Multiple
- Traditional Control
- Oral Nutritional Supplement
- (no location specified)
Jul 12, 2022
Plasma Cell Myeloma, Transplant-Related Carcinoma Trial in Seattle (Ixazomib Citrate, Laboratory Biomarker Analysis,
Active, not recruiting
- Plasma Cell Myeloma
- Transplant-Related Carcinoma
- Ixazomib Citrate
- +2 more
-
Seattle, WashingtonFred Hutchinson Cancer Research Center
Jul 12, 2022
The Indiana Myeloma Registry
Recruiting
- Plasma Cell Dyscrasias
- This is a non-interventional trial
-
Indianapolis, IndianaIndiana University Simon Cancer Center
Mar 2, 2022
Multiple Myeloma Trial in Houston (Belantamab mafodotin)
Not yet recruiting
- Multiple Myeloma
- Belantamab mafodotin
-
Houston, TexasM D Anderson Cancer Center
Jul 31, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
Jun 14, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Laboratory Biomarker Analysis, Lenalidomide,
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic
Dec 1, 2021
Stratification in Multiple Myeloma Based on Fluorescence Flow
Recruiting
- Myeloma Multiple
- fluorescence flow cytometry
-
Saint Petersburg, Russian FederationBoris V Afanasyev, MD, Prof.
Jul 19, 2022